Par Drugs & Chemicals Ltd (PAR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003142,
    "name": "Par Drugs & Che.",
    "stock_name": "Par Drugs & Che.",
    "full_name": "Par Drugs & Chemicals Ltd",
    "name_url": "stocks-analysis/par-drugs-che",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "96.84",
    "chg": 8.99,
    "chgp": "10.23%",
    "dir": 1,
    "prev_price": "87.85",
    "mcapval": "108.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "PAR",
    "ind_name": "Chemicals & Petrochemicals",
    "ind_code": 11,
    "indexname": "",
    "isin": "INE04LG01015",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 170453,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/par-drugs-che-1003142-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Par Drugs & Che. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-che-upgraded-from-strong-sell-to-sell-by-marketsmojo-3748059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParDrugsChe_mojoScore_3748059.png",
        "date": "2025-12-05 10:11:01",
        "description": "Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions."
      },
      {
        "title": "Is Par Drugs & Che. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-par-drugs-che-overvalued-or-undervalued-3710201",
        "imagepath": "",
        "date": "2025-11-18 08:29:41",
        "description": "As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. \n\nIn comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present...."
      },
      {
        "title": "Par Drugs & Chemicals Q2 FY26: Profit Rebound Masks Underlying Margin Pressure",
        "link": "https://www.marketsmojo.com/news/result-analysis/par-drugs-chemicals-q2-fy26-profit-rebound-masks-underlying-margin-pressure-3718448",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParDrugsChemica_quaterlyResult_3718448.png",
        "date": "2025-11-15 10:58:28",
        "description": "Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45."
      },
      {
        "title": "How has been the historical performance of Par Drugs & Che.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-par-drugs-che-3699683",
        "imagepath": "",
        "date": "2025-11-13 23:46:17",
        "description": "Answer:\nThe historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.\n\nBreakdown:\nPar Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantl..."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3681600",
        "imagepath": "",
        "date": "2025-11-08 00:05:41",
        "description": "As of 07-Nov, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 98.73, reflecting a decrease of 0.45 or 0.45%. The stock has underperformed its sector by 0.49% today and is trading below all major moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 3.37%, and its year-to-date performance shows a significant decline of 50.36%. Despite a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 1.2, the company has reported negative results for the last three consecutive quarters, contributing to a substantial 67.00% drop in returns over the past year. Additionally, the company's net sales growth has been modest at 12.10% annually over the last five years, and its profits have decreased by 2.8%, further impacting investor sentiment.\n\nIn the broader market context, the Sensex has shown a slight increase of 7.81% y..."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3575574",
        "imagepath": "",
        "date": "2025-09-26 23:15:25",
        "description": "As of 26-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 104.06, which reflects a decrease of 4.42 or 4.07%. The stock has underperformed its sector by 2.08% today, and while it is trading above its 50-day and 100-day moving averages, it is below its 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.64%, and its year-to-date performance shows a significant decline of 47.68%. The company has faced negative results for the last three consecutive quarters, with a reported profit after tax decline of 20.32% in the latest six months, contributing to the stock's poor performance.\n\nIn the broader market context, the BSE Small Cap index has also fallen by 2.05%, indicating a challenging environment for small-cap stocks. Compared to the benchmark Sensex, which has seen a decline of 2.65% over the past week, Par Drugs' performance is n..."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3568322",
        "imagepath": "",
        "date": "2025-09-24 23:21:05",
        "description": "As of 24-Sep, Par Drugs & Chemicals Ltd is experiencing a price increase, currently at 110.95, reflecting a change of 1.88 or 1.72% upward. The stock has shown mixed performance over various time frames; it has decreased by 4.85% over the past week but increased by 12.38% over the last month. Today's price summary indicates that the stock is outperforming its sector by 2.21% and is trading above its 20-day, 50-day, and 100-day moving averages, although it is below its 5-day and 200-day moving averages. The company has a low debt-to-equity ratio and a favorable return on equity of 14.3, suggesting an attractive valuation relative to its peers, despite a significant decline of 53.05% over the past year.\n\nIn the broader market context, while the stock has underperformed the market significantly over the past year, it has shown resilience in the short term compared to the benchmark, which has only declined by 1..."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3562289",
        "imagepath": "",
        "date": "2025-09-23 23:31:23",
        "description": "As of 23-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 109.07, which reflects a decrease of 3.35 or 2.98%. The stock has underperformed its sector today by 2.42%, and while it is trading above its 20-day, 50-day, and 100-day moving averages, it is below its 5-day and 200-day moving averages. Over the past week, the stock has decreased by 1.78%, and its year-to-date performance shows a significant drop of 45.16%. The company has faced challenges, including negative results for the last three consecutive quarters and a substantial year-over-year decline of 55.19% in stock returns, indicating poor long-term growth prospects despite a low debt-to-equity ratio and attractive valuation metrics.\n\nIn the broader market context, the stock's recent performance contrasts sharply with the benchmark, as the Sensex has only declined by 0.28% over the past week and has gained 6...."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3555524",
        "imagepath": "",
        "date": "2025-09-22 23:21:56",
        "description": "As of 22-Sep, Par Drugs & Chemicals Ltd is experiencing a slight decline in its stock price, currently at 112.42, reflecting a decrease of 0.25 or 0.22%. The stock has shown a strong performance over the past week and month, with returns of 6.29% and 13.87%, respectively, outperforming the Sensex, which returned 0.53% and 1.34% in the same periods. However, despite these short-term gains, the stock has significantly underperformed over the year, with a staggering decline of 53.87%. The company has a low debt-to-equity ratio and an attractive return on equity of 14.3, but it has also reported negative results for the last three consecutive quarters, contributing to its poor long-term growth outlook.\n\nIn the broader market context, while the stock has outperformed the sector today, it has still underperformed the market over the past year, where the BSE500 index recorded a negative return of 3.80%. The compan..."
      }
    ],
    "total": 102,
    "sid": "1003142",
    "stock_news_url": "https://www.marketsmojo.com/news/par-drugs-chemicals-1003142"
  },
  "announcements": [
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding Board meeting held on November 11, 2019.",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Outcome of Board Meeting",
      "datetime": "13-Nov-2019"
    },
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange that the Company has fixed Record Date as November 25, 2019 for the purpose of INTERIM DIVIDEND",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Record Date",
      "datetime": "04-Nov-2019"
    },
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding 'WHO-GMP Certification'.",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Updates",
      "datetime": "30-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Par Drugs & Chemicals Ltd has declared <strong>12%</strong> dividend, ex-date: 22 Nov 21",
          "dt": "2021-11-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Par Drugs & Chemicals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 27 Apr 21",
          "dt": "2021-04-27",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Par Drugs & Che. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-05 10:11:01

Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions.

Is Par Drugs & Che. overvalued or undervalued?

2025-11-18 08:29:41

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present....

Par Drugs & Chemicals Q2 FY26: Profit Rebound Masks Underlying Margin Pressure

2025-11-15 10:58:28

Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45.

How has been the historical performance of Par Drugs & Che.?

2025-11-13 23:46:17

Answer: The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics. Breakdown: Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantl...

Why is Par Drugs & Che. falling/rising?

2025-11-08 00:05:41

As of 07-Nov, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 98.73, reflecting a decrease of 0.45 or 0.45%. The stock has underperformed its sector by 0.49% today and is trading below all major moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 3.37%, and its year-to-date performance shows a significant decline of 50.36%. Despite a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 1.2, the company has reported negative results for the last three consecutive quarters, contributing to a substantial 67.00% drop in returns over the past year. Additionally, the company's net sales growth has been modest at 12.10% annually over the last five years, and its profits have decreased by 2.8%, further impacting investor sentiment. In the broader market context, the Sensex has shown a slight increase of 7.81% y...

Why is Par Drugs & Che. falling/rising?

2025-09-26 23:15:25

As of 26-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 104.06, which reflects a decrease of 4.42 or 4.07%. The stock has underperformed its sector by 2.08% today, and while it is trading above its 50-day and 100-day moving averages, it is below its 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.64%, and its year-to-date performance shows a significant decline of 47.68%. The company has faced negative results for the last three consecutive quarters, with a reported profit after tax decline of 20.32% in the latest six months, contributing to the stock's poor performance. In the broader market context, the BSE Small Cap index has also fallen by 2.05%, indicating a challenging environment for small-cap stocks. Compared to the benchmark Sensex, which has seen a decline of 2.65% over the past week, Par Drugs' performance is n...

Why is Par Drugs & Che. falling/rising?

2025-09-24 23:21:05

As of 24-Sep, Par Drugs & Chemicals Ltd is experiencing a price increase, currently at 110.95, reflecting a change of 1.88 or 1.72% upward. The stock has shown mixed performance over various time frames; it has decreased by 4.85% over the past week but increased by 12.38% over the last month. Today's price summary indicates that the stock is outperforming its sector by 2.21% and is trading above its 20-day, 50-day, and 100-day moving averages, although it is below its 5-day and 200-day moving averages. The company has a low debt-to-equity ratio and a favorable return on equity of 14.3, suggesting an attractive valuation relative to its peers, despite a significant decline of 53.05% over the past year. In the broader market context, while the stock has underperformed the market significantly over the past year, it has shown resilience in the short term compared to the benchmark, which has only declined by 1...

Why is Par Drugs & Che. falling/rising?

2025-09-23 23:31:23

As of 23-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 109.07, which reflects a decrease of 3.35 or 2.98%. The stock has underperformed its sector today by 2.42%, and while it is trading above its 20-day, 50-day, and 100-day moving averages, it is below its 5-day and 200-day moving averages. Over the past week, the stock has decreased by 1.78%, and its year-to-date performance shows a significant drop of 45.16%. The company has faced challenges, including negative results for the last three consecutive quarters and a substantial year-over-year decline of 55.19% in stock returns, indicating poor long-term growth prospects despite a low debt-to-equity ratio and attractive valuation metrics. In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as the Sensex has only declined by 0.28% over the past week and has gained 6....

Why is Par Drugs & Che. falling/rising?

2025-09-22 23:21:56

As of 22-Sep, Par Drugs & Chemicals Ltd is experiencing a slight decline in its stock price, currently at 112.42, reflecting a decrease of 0.25 or 0.22%. The stock has shown a strong performance over the past week and month, with returns of 6.29% and 13.87%, respectively, outperforming the Sensex, which returned 0.53% and 1.34% in the same periods. However, despite these short-term gains, the stock has significantly underperformed over the year, with a staggering decline of 53.87%. The company has a low debt-to-equity ratio and an attractive return on equity of 14.3, but it has also reported negative results for the last three consecutive quarters, contributing to its poor long-term growth outlook. In the broader market context, while the stock has outperformed the sector today, it has still underperformed the market over the past year, where the BSE500 index recorded a negative return of 3.80%. The compan...

View All News